SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
ANDRX CORPORATION
- -------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE
- -------------------------------------------------------------------------------
(Title of Class of Securities)
034551101
- -------------------------------------------------------------------------------
(CUSIP Number)
Check the following box if a fee is being paid with this statement |_|. (A fee
is not required only if the filing person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7).
Page 1 of 5 Pages
There are no exhibits
<PAGE>
CUSIP NO. 034551101
(1) Names of Reporting Persons WATSON PHARMACEUTICALS, INC.
------------------------------------------
S.S. or I.R.S. Identification Nos. of Above Persons 95-3872914
(2) Check the Appropriate Box if a Member of a Group
(See Instructions (a) [ ] (b) [ ]
(3) SEC Use Only
(4) Citizenship or Place of Organization NV
Number of (5) Sole Voting Power 2,428,869 1
Shares Bene-
ficially (6) Shared Voting Power 0
Owned by
Each Report- (7) Sole Dispositive Power 2,428,869 2
ing Person
With (8) Shared Dispositive Power 0
(9) Aggregate Amount Beneficially Owned by Each Reporting
Person 2,428,8693
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)[ ]
(11) Percent of Class Represented by Amount in Row (9) 18.11 4
(12) Type of Reporting Person (See Instructions) CORPORATION
- --------
1 Includes 337,079 shares of Common Stock issuable upon exercise of
warrants.
2 Includes 337,079 shares of Common Stock issuable upon exercise of
warrants.
3 Includes 337,079 shares of Common Stock issuable upon exercise of
warrants.
4 Calculated on the basis of 13,414,709 shares of Common Stock
outstanding on December 31, 1996.
Page 2 of 5 Pages
There are no exhibits
<PAGE>
Item 1(a). Name of Issuer:
ANDRX CORPORATION
Item 1(b). Address of Issuer's Principal Executive Office:
4001 SW 47th Avenue, Suite 201
Fort Lauderdale, Florida 33314
Item 2(a). Name of Person Filing:
Watson Pharmaceuticals, Inc.
Item 2(b). Address of Principal Business Office:
311 Bonnie Circle
Corona, California 91720
Item 2(c). Citizenship:
N/A
Item 2(d). Title of Class of Securities:
Common Stock, $.001 Par Value
Item 2(e). CUSIP Number:
034551101
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or
13d-2(b), identify the status of the person filing.
Not applicable
Item 4. Ownership:
(a) Amount beneficially Owned: 2,428,8691 SHARES
(b) Percent of Class: 18.112%
- --------
1 Includes 337,079 shares of Common Stock issuable upon exercise of
warrants.
2 Calculated on the basis of 13,414,709 shares of Common Stock
outstanding on December 31, 1996.
Page 3 of 5 Pages
There are no exhibits
<PAGE>
<TABLE>
<CAPTION>
(c) Number of shares as to which such person has:
<S> <C> <C>
(i) sole power to vote or to direct the vote 2,428,869 3
(ii) shared power to vote or to direct the vote 0
(iii) sole power to dispose or to direct the disposition of 2,428,969 4
(iv) shared power to dispose or to direct the disposition of 0
</TABLE>
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following [ ]
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding
Company.
Not applicable
Item 8. Identification and Classification of Members of the Group.
Not applicable
Item 9. Notice of Dissolution of Group.
Not applicable
Item 10. Certification.
Not applicable
- --------
3 Includes 337,079 shares of Common Stock issuable upon exercise of
warrants.
4 Includes 337,079 shares of Common Stock issuable upon exercise of
warrants.
Page 4 of 5 Pages
There are no exhibits
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
WATSON PHARMACEUTICALS, INC.
February 13, 1997 By:________________________________
Name:______________________________
Title:_____________________________
Page 5 of 5 Pages
There are no exhibits
